Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1.

Reck M, Ciuleanu TE, Lee JS, Schenker M, Zurawski B, Kim SW, Mahave M, Alexandru A, Peters S, Pluzanski A, Caro RB, Linardou H, Burgers JA, Nishio M, Martinez-Marti A, Azuma K, Axelrod R, Paz-Ares LG, Ramalingam SS, Borghaei H, O'Byrne KJ, Li L, Bushong J, Gupta RG, Grootendorst DJ, Eccles LJ, Brahmer JR

Open source

DOI: 10.1016/j.jtho.2023.04.021
Published: 2023 Aug
Container: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jtho.2023.04.021,
  title = {Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1.},
  author = {Reck M and Ciuleanu TE and Lee JS and Schenker M and Zurawski B and Kim SW and Mahave M and Alexandru A and Peters S and Pluzanski A and Caro RB and Linardou H and Burgers JA and Nishio M and Martinez-Marti A and Azuma K and Axelrod R and Paz-Ares LG and Ramalingam SS and Borghaei H and O'Byrne KJ and Li L and Bushong J and Gupta RG and Grootendorst DJ and Eccles LJ and Brahmer JR},
  year = {2023},
  journal = {Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  doi = {10.1016/j.jtho.2023.04.021},
  url = {https://doi.org/10.1016/j.jtho.2023.04.021}
}

RIS

TY  - JOUR
TI  - Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1.
AU  - Reck M
AU  - Ciuleanu TE
AU  - Lee JS
AU  - Schenker M
AU  - Zurawski B
AU  - Kim SW
AU  - Mahave M
AU  - Alexandru A
AU  - Peters S
AU  - Pluzanski A
AU  - Caro RB
AU  - Linardou H
AU  - Burgers JA
AU  - Nishio M
AU  - Martinez-Marti A
AU  - Azuma K
AU  - Axelrod R
AU  - Paz-Ares LG
AU  - Ramalingam SS
AU  - Borghaei H
AU  - O'Byrne KJ
AU  - Li L
AU  - Bushong J
AU  - Gupta RG
AU  - Grootendorst DJ
AU  - Eccles LJ
AU  - Brahmer JR
PY  - 2023
JO  - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
DO  - 10.1016/j.jtho.2023.04.021
UR  - https://doi.org/10.1016/j.jtho.2023.04.021
ER  -

APA

M, R., TE, C., JS, L., M, S., B, Z., SW, K., M, M., A, A., S, P., A, P., RB, C., H, L., JA, B., M, N., A, M., K, A., R, A., LG, P., SS, R., H, B., KJ, O., L, L., J, B., RG, G., DJ, G., LJ, E., & JR, B. (2023). Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. https://doi.org/10.1016/j.jtho.2023.04.021

Source records

pubmed · retrieved 2026-09-25T18:34:20.649Z